⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

March 25, 2026Kidney International ReportsOpen Access

WCN26-8180 Phase 1 Study Evaluating Hydrogel-formulated UC-MSCs Administered Subcutaneously in Addition to Standard of Care as a Treatment for Lupus Nephritis

View Full Paper

Ask AI

Bookmark

Share

Key Points

This study investigates the effectiveness and safety of hydrogel-formulated umbilical cord mesenchymal stem cells (UC-MSCs) for treating lupus nephritis.
Phase 1 clinical trial design
Administration of UC-MSCs subcutaneously in addition to standard care
Monitoring safety and efficacy outcomes over a defined period
Reduction in urinary protein levels observed
Safety profile consistent with existing data
No significant increase in adverse events compared to standard care

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Phase 1 study evaluates hydrogel UC-MSC treatment for lupus nephritis, indicating potential long-term benefits.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Alon Yaar (2026) studied this question.

synapsesocial.com/papers/69c770c08bbfbc51511e0b9c https://doi.org/10.1016/j.ekir.2026.106403

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trialother · 2023 · 72 citations
2Effect of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Level and Diabetes Duration: An Exploratory Analysis of the FINE-ONE TrialOriginal Research · 2026 · 1 citations
3#1350 Finerenone in real-life clinical practice: first results from a pilot study2024
4WCN26-7847 Kaempferol-enriched fraction form Camellia sinensis mitigates diabetic kidney disease by targeting the sonic hedgehog pathway: Evidence from in vitro and in vivo studiesIn Vitro Study · 2026
5Change in Urine Albumin-Creatinine Ratio and Occurrence of Hyperkalemia in Patients Initiating Finerenone in the USA: A Cohort Study from the FOUNTAIN Platformcohort · 2025 · 13 citations
6Finerenone in diabetic kidney disease: Findings from a single-center retrospective observational studycohort · 2026
7Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trialsmeta-analysis · 2022 · 37 citations
8Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor TherapyRCT · 2021 · 159 citations
9The PLANET-KT Randomized Controlled Trial: Plant-Based Diet Beyond Blood Pressure ControlKidney International Reports · 2026
10From Molecular Signal to Clinical Action in Cardiovascular-Kidney-Metabolic DiseaseKidney International Reports · 2026

More from Kidney International Reports

More from Tishk International University